BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...

September 25, 2026 | News

DKSH Launches Colpofix in Singapore to Support Women with HPV-Related Cervical Lesions

Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, with DKSH's launch of Colpofix&...

September 22, 2026 | News

IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer

MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...

September 21, 2026 | News

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

Sorbent Enters Feminine Hygiene Market with Stayfree and Carefree Acquisition in Australia and New Zealand

Sorbent Paper Company Pty Ltd ("Sorbent") has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care b...

September 15, 2026 | News

Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...

September 15, 2026 | News

Hims & Hers Enters APAC Market with Australia Launch Following Eucalyptus Acquisition

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, announced it is now serving customers in Australia, marki...

September 03, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

September 03, 2026 | News

US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...

August 27, 2026 | News

Metabolon Completes Gates Foundation-Funded Metabolomics Studies to Advance Women’s and Infant Health

nnovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations fro...

August 27, 2026 | News

China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer

Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...

August 13, 2026 | News

Haleon, A*STAR Launch Centrum Study on Metabolic Health in Midlife Asian Women

A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a g...

August 12, 2026 | News

Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...

August 03, 2026 | News

EU CHMP Backs Enhertu Plus Pertuzumab as First New First-Line HER2 Positive Metastatic Breast Cancer Treatment in Over a Decade

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by ...

July 28, 2026 | News

Stay Connected